Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer

Byun, Young Joon; Piao, Xuan Mei; Jeong, Pildu; Kang, Ho Won; Seo, Soonjoo; Moon, Sung Joon; Lee, Jong‐Young; Choi, Yung Hyun; Lee, Hee Youn; Kim, Dong-Won; Lee, Sang Cheol; Jong, Eun; Yun, Seok Joong; Kim, Wun-Jae

doi:10.4111/icu.20200488

Cited by 17 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, we calculated the ratio of the expression of two genes, which does not require an internal control. A similar approach was previously used by our group to analyze urinary cell-free DNA and urinary miRNAs [ 14 25 26 ]. Analysis of the ratio of urinary miRNAs is a relatively simple method that shows good reproducibility and could thus be applied in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…In previous work from our group, we performed a urine miRNA array and identified differentially expressed urinary miRNAs between PCa and benign prostatic hyperplasia (BPH) controls [ 13 14 15 ]. Two candidate urinary miRNAs (hsv2-miR-H9 and hsa-miR-3659) were sequentially validated in urine [ 13 14 ]. Initially, urinary miRNA expression was normalized to the total RNA concentration using the Quant-iT Ribo-Green RNA Reagent and Kit (Invitrogen, Grand Island, NY, USA) [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone

et al. 2022

Self Cite

View full text Add to dashboard Cite

Purpose Tumor microRNAs (miRNAs) are released to biofluids directly or indirectly. Although urinary miRNAs are promising non-invasive biomarkers for the diagnosis of prostate cancer (PCa), their clinical application is challenging for technical reasons. We examined the efficacy of urinary hsv2-miR-H9 to hsa-miR-3659 ratio as a non-invasive diagnostic biomarker of PCa. Materials and Methods The expression of urinary miRNAs was quantified by real-time PCR in 116 samples from 53 patients with benign prostatic hyperplasia (BPH) and 63 patients with PCa. The miRNA expression ratio was calculated using an upregulated miRNA (hsv2-miR-H9) as the numerator and a downregulated miRNA (hsa-miR-3659) as the denominator. Results The urinary miR-H9 to miR-3659 ratio was significantly higher in PCa than in BPH controls (p<0.001). The diagnostic accuracy of the urinary miRNA expression ratio was comparable with that of prostate-specific antigen (PSA) (receiver operating characteristic [ROC] curve comparison, p=0.287). The area under the curve for urinary miRNA expression ratio was 0.862 and that for PSA was 0.642 in the “PSA gray zone” (3–10 ng/mL) (ROC curve comparison, p=0.034). The use of the urinary miRNA expression ratio would have prevented 70.6% of unnecessary prostate biopsies; however, 28.6% of PCa cases could be missed in patients within the PSA gray zone. Conclusions The expression ratio of urinary miR-H9 to miR-3659 could be a relevant non-invasive biomarker for PCa diagnosis, particularly for patients within the PSA gray zone.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, there is a growing appreciation of the roles of miRNAs in the diagnosis, treatment, and prognosis prediction of cancers, as evidenced by the increase in the number of studies on this topic recently. Zheng et al reported that miR-4651 inhibits to microRNA-3659 expression ratio is potentially a noninvasive diagnostic biomarker for PCa (18). Circulating miR-940 was illuminated to not only play a prominent role in PCa progression but is also a novel biomarker for PCa detection (19).…”

Section: Discussionmentioning

confidence: 99%

A novel prognostic model based on three clinic-related miRNAs for prostate cancer

Che

Jiang²,

Zhang³

et al. 2022

Front. Surg.

View full text Add to dashboard Cite

BackgroundProstate cancer (PCa) is the second most common malignant tumor in men worldwide. MiRNAs have been reported to play significant roles in prognosis prediction for patients with malignant tumors.MethodsThe survival-related miRNAs (sDMIRs) were identified by Cox regression analysis. A risk score model (RSM) was established based on three sDMIRs. The expression levels of sDMIRs in cell lines and clinical samples were detected via quantitative polymerase chain reaction. The correlations between sDMIRs and clinicopathological characteristics of PCa patients were evaluated using the chi-square test and Fisher's exact probability method.ResultsFour sDMIRs were remarkably related to the prognosis of PCa patients based on univariate Cox analysis, of which miR-10a-5p, miR-20a-5p, and miR-508-3p were used to establish the RSM. The OS in the low-risk group was better than that in the high-risk group. In the verification of various prostate cell lines and clinical samples from 162 PCa patients, the prominently higher expression of miR-10a-5p and miR-20a-5p and lower expression of miR-508-3p were detected in PCa cell lines and tumor tissues, especially the more advanced T-stage. Besides, the higher expression of miR-20a-5p and miR-10a-5p was significantly correlated to the higher level of PSA, Gleason score, more advanced T-stage, and distant metastasis status.ConclusionWe identify and validate the clinical significance of three sDMIRs and establish a verified RSM to evaluate the prognosis for PCa patients. The findings not only provide a reliable tool for clinical decision-makers to evaluate patients' prognosis but also offer a novel perspective into the field of biomarker identification.

show abstract

“…On the subset of 12 miRNAs that showed significant differences between PCa and BPH samples, they used a ratio analysis, since urinary levels of upregulated miRNAs were compared with levels of downregulated miR-3659. For subsequent validation, the urinary miR-1913 to miR-3659 ratio was selected, where it was significantly higher in PCa than in BPH, with even improved diagnostic power within the PSA gray zone (AUC = 0.82) [32]. ↑ miR-375, ↑ let-7c [42] PCa-prostate cancer, HC-healthy controls, BPH-benign prostatic hyperplasia, ↑-upregulated in PCa, ↓-downregulated in PCa.…”

Section: Urinary Cell-free Mirnasmentioning

confidence: 99%

Urinary microRNAs and Their Significance in Prostate Cancer Diagnosis: A 5-Year Update

Juráček

Mądrzyk

Staník

et al. 2022

Cancers

View full text Add to dashboard Cite

Current routine screening methods for the diagnosis of prostate cancer (PCa) have significantly increased early detection of the disease but often show unsatisfactory analytical parameters. A class of promising markers represents urinary microRNAs (miRNAs). In the last five years, there has been an extensive increase in the number of studies on this topic. Thus, this review aims to update knowledge and point out technical aspects affecting urinary miRNA analysis. The review of relevant literature was carried out by searching the PubMed database for the keywords: microRNA, miRNA, urine, urinary, prostate cancer, and diagnosis. Papers discussed in this review were retrieved using PubMed, and the search strategy was as follows: (urine OR urinary) WITH (microRNA OR miRNA) AND prostate cancer. The search was limited to the last 5 years, January 2017 to December 2021. Based on the defined search strategy, 31 original publications corresponding to the research topic were identified, read and reviewed to present the latest findings and to assess possible translation of urinary miRNAs into clinical practice. Reviews or older publications were read and cited if they valuably extended the context and contributed to a better understanding. Urinary miRNAs are potentially valuable markers for the diagnosis of prostate cancer. Despite promising results, there is still a need for independent validation of exploratory data, which follows a strict widely accepted methodology taking into account the shortcomings and factors influencing the analysis.

show abstract

Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer

Cited by 17 publications

References 29 publications

Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone

Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone

A novel prognostic model based on three clinic-related miRNAs for prostate cancer

Urinary microRNAs and Their Significance in Prostate Cancer Diagnosis: A 5-Year Update

Contact Info

Product

Resources

About